What Baxter's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Baxter filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses compliance burden, digital transformation and product liability.
Public (BAX)Medical Equipment Manufacturing10,000+ employeesbaxter.comLinkedIn
Get Baxter's live signals in Claude or ChatGPT, or by API
What changed at Baxter this week? Use Autobound signals for baxter.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 27
Source: Autobound Signal API · 62 signals tracked for Baxter · updated
10-Q · latest 10
What Baxter's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Baxter halted Novum LVP distribution following FDA Class I recall classification
The FDA classified Baxter's voluntary corrections for the Novum LVP as Class I recalls, prompting a temporary stop on distribution and installation in the U.S.
Baxter reorganizes business into two reportable segments under a new operating model
In Q2 2026, Baxter implemented a new operating model, consolidating its structure into two segments: Medical Products & Therapies and Healthcare Systems & Technologies, while folding Pharmaceuticals into Infusion Therapies & Platforms.
Baxter incurs $54 million YTD for enterprise-wide systems modernization and digital capabilities
Baxter recorded $20 million in Q3 2026 and $54 million for the first nine months of 2026 in business transformation costs for enterprise-wide initiatives to modernize systems and enhance digital capabilities.
$54M
business transformation costs for enterprise-wide initiatives to modernize and simplify systems and enhance digital capabilities
Baxter reports injectables sales headwinds and supply chain constraints across international markets
Baxter experienced lower sales in its Injectables portfolio during the first nine months of 2026 due to ongoing supply constraints across U.S.
Baxter incurred $3M in Q3 2026 complying with EU medical devices regulations
Baxter recorded $3 million in Q3 2026 and $11 million year-to-date in third-party and contractor costs to comply with the European Union's medical device regulations for previously registered products.
$3M
incremental costs to comply with European Union medical device regulations in Q3 2026
- SEC EDGAR
10-Q
Filed · 10 signals
Baxter reports experiencing IT system breakdowns from obsolescence and cyber breaches.
The company has experienced failures in its IT systems, explicitly citing obsolescence, cyber breaches, and data leakage as causes.
artificial intelligence (AI)machine learning
The company is incurring significant costs for employee severance and contract terminations as part of ongoing optimization programs.
Baxter addresses FDA Warning Letter at India plant and notes quality issues with Novum LVP product.
The company recently resolved a 2023 FDA Warning Letter at its Ahmedabad, India facility, indicating intense focus on manufacturing and quality compliance.
Baxter acknowledges experiencing past cybersecurity breaches and data leakage incidents.
The company explicitly states it has experienced cybersecurity breaches and data leakage, creating significant operational and reputational risk.
IT system 'obsolescence' cited as a cause for breakdowns and security breaches at Baxter.
Baxter identifies system 'obsolescence' as a direct cause of IT breakdowns and security vulnerabilities.
Earlier 10-Q filings
- 10-QFiled · 12 signalsSEC EDGAR
Showing 10 of 27 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Baxter earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Product issues are causing customers to evaluate competitor infusion pumps.The company explicitly acknowledges that the delay in resolving the Novum IQ pump issue is leading customers to evaluate alternative solutions, signaling a direct risk of market share loss. This makes Baxter highly receptive to solutions that can help retain customers or improve their competitive positioning. | |
| Launching new 'data-driven' growth and performance system (GPS).New CEO Andrew Hider is rolling out a company-wide, data-driven system called 'Baxter GPS' to drive continuous improvement and a performance mindset. This creates significant opportunities for vendors specializing in analytics, business intelligence, performance management software, and operational excellence consulting. | |
| Lowered full-year 2025 operational sales and earnings guidance.The company reduced its operational sales growth forecast from 3-4% to 1-2% and lowered its EPS guidance, citing challenges with infusion pumps and product softness. This financial pressure makes them more receptive to solutions that can drive efficiency, cut costs, or recover revenue. | |
| Cutting dividend to free up over $300M annually for aggressive deleveraging.Baxter is prioritizing balance sheet strength by reducing its dividend to accelerate deleveraging, aiming for a 3x net leverage target by the end of 2026. This sharp focus on financial health signals a need for cost-control measures, financial planning software, and efficiency-driving solutions to maximize cash flow. | |
| Facing margin pressure from increased manufacturing, supply, and procurement costs.The company is experiencing higher costs across its supply chain, which is negatively impacting operating margins in both the Medical Products and Pharmaceuticals segments. This creates an urgent need for solutions that can optimize supply chain logistics, reduce manufacturing overhead, or improve procurement efficiency. | |
| Cutting dividend to free up over $300M annually for debt reduction.The company is taking decisive action to strengthen its balance sheet by cutting its dividend, freeing up significant cash flow explicitly for deleveraging. This signals a strong focus on financial discipline and cost control over expansive new spending initiatives. |
Signal API · MCP
Track Baxter with the Signal API
One POST /v1/companies/enrich call with baxter.com returns Baxter 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"baxter.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Baxter 10-Q
When did Baxter file its latest 10-Q?
What did Baxter disclose in its latest 10-Q?
What did Baxter say on its recent earnings calls?
Where can I read Baxter's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .